Skip to main content
×
×
Home

New drugs for Alzheimer's disease

  • Alistair Burns (a1), Eve Russell (a1) and Sean Rage (a1)
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      New drugs for Alzheimer's disease
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      New drugs for Alzheimer's disease
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      New drugs for Alzheimer's disease
      Available formats
      ×
Abstract
Copyright
Corresponding author
Professor A. Burns, Department of Psychiatry, University of Manchester, Withington Hospital, Manchester M20 8LR, UK. Tel: 0161 291 3310: Fax: 0161 291 4364
References
Hide All
Anand, R. & Gharabini, G. (1996) Clinical development of Exelon. The ADENA programme. Journal of Drug Development and Clinical Practice. 8, 117122
Anonymous (1998) Donepezil update. Drugs and Therapeutics Bulletin. 36, 6061.
Anonymous (1999) Donepezil for Alzheimer's disease. Drugs and Therapeutics Bulletin, 35, 7576
Bosanquet, N., May, J. & Johnson, N. (1998) Alzheimer's Disease in the United Kingdom Burden of Disease and Future Care Health Policy Review Paper No. 12. London: Health Policy Unit. Imperial College School of Medicine
Burns, A. & Murphy, D. (1996) Protection against Alzheimer's disease Lancet 348 420421
Burns, A., Rossor, M., Hecker, J., et al (1999) The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dementia and Geriatric Cognitive Disorders, 10, 237244.
Committee lor Proprietary Medicinal Products (CPMP) (1997) Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease London: European Agency for the Evaluation of Medicinal Products.
Cummings, J., Megam, M. & Gray, K. (1994) The Neuropsychiatric Inventory. Neurology. 44. 23082314
de Jong, R., Osterlund, O. & Roy, G. (1989) Measurement of quality of life changes in patients with Alzheimer's disease. Clinical Therapeutics, 11, 545555.
Dening, T. & Lawton, C. (1998) Doctors want to offer more than sympathy. British Medical Journal, 317. 945.
Glennie, G. (1997) The efficacy of tacrine and the measurement of outcomes in Alzheimer's disease. In Technology Overview: Pharmaceuticals, issue 5. Ottawa: Canadian Co-ordinating Office for Health Technology Assessment.
Gortelmeyar, R., Kante, M., Parsons, C., et al (1993) The treatment of dementia syndrome with ecotonal memantine. In Spectrum KTRUM der Negro-rehabilitation (ed. W. Von Wild), pp. 5056. Munich: Zuckschwerdt.
Harvey, R. (1999) A review and commentary on a sample of 15 UK guidelines for the drug treatment of Alzheimer's disease. International journol of Geriatric Psychiatry, in press.
Herman, A., Rocca, W., Brayne, C., et al (1991) The prevalence of dementia in Europe. International Journal of Epidemiology, 20, 736748.
Knopman, D., Knapp, M., Gracon, S., et al (1994) The Clinician Interview Based Impression (CIBI) Neurology, 44, 23152321.
Le Bars, P., Katz, M., Berman, N., et al (1997) A placebo controlled double blind randomised trial of an extract of Ginkgo biloba for dementia. Journal of the American Medical Association, 278, 13271332.
Leber, R (1990) Guidelines for the Clinical Evaluation of Anti-Dementia Drugs. Open Letter to the Pharmaceutical Industry Washington, DC: Food and Drug Administration.
Lovestone, S., Graham, N. & Howard, R. (1997) Guidelines on drug treatment for Alzheimer's disease. Lancet, 350, 232233.
McKeith, L. (1988) The clinical trial protocol of Metrifonate in Alzheimer's Trial (MALT). Dementia & Geriatric Cognitive Disorders, 9 (suppl. 2), 27.
Morris, J., Cyrus, P., Orazem, J., et al (1998) Metrifonate benefits cognitive, behavioural and global function in patients with Alzheimer's disease. Neurology, 50, 12221230.
Rogers, S. & Friedhoff, L (1996) The efficacy and safety of donepezil in patients with Alzheimer's disease. Dementia, 7, 293303.
Rogers, S. & Friedhoff, L (1998) Long-term efficacy and safety of donepezil and the treatment of Alzheimer's disease. European Neuropsychopharmacology, 8, 6775.
Rogers, S., Fariow, M., Doody, R., et al (1998a) A 24-week double-blind placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50, 136145.
Rogers, S., Doody, R., Mohs, R., et al (1998b) Donepezil improves cognition and global function in Alzheimer's disease. Archives of Internal Medicine, 158, 10211031.
Rosen, W., Mohs, R. & Davies, K. (1984) A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 13561364.
Rother, M., Eridnjunti, T., Roessner, M., et at (1998) Propentofylline in the treatment of Alzheimer's disease and vascular dementia. A review of Phase 3 trials. Dementio & Geriatric Cognitive Disorders, 9 (suppl. 1). 3643.
Sana, M., Ernesto, C., Thomas, R., et al (1997) A controlled trial of selegiline, alpha tocopherol or both as treatment for Alzheimer's disease. New England Journal of Medicine, 336, 12161222.
Schneider, L, Olin, J., Doody, R., et el (1997) Validity and reliability of the Alzheimer's Disease Co-Operative Study - clinical global impression of change. Alzheimer's Disease and Associated Disorders, 11 (suppl. 2). S22S32.
Standbig Medical Advisory Committee (SMAC) (1998) The Use of Donepezil for Alzheimer's Disease. London: Department of Health.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 10 *
Loading metrics...

Abstract views

Total abstract views: 67 *
Loading metrics...

* Views captured on Cambridge Core between 3rd January 2018 - 25th June 2018. This data will be updated every 24 hours.

New drugs for Alzheimer's disease

  • Alistair Burns (a1), Eve Russell (a1) and Sean Rage (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *